RxDoctor Payments Data

David Miller, MD

Family Medicine · San Diego, CANPI 1083949739

Payments from drug & device makers

$3,438in general payments, 2019–2025

Across 172 payments — averaging $19.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$817
  • AbbVie$357
  • Amgen$319
  • AstraZeneca$296
  • Merck$219
  • Takeda Pharmaceuticals U.S.A., Inc.$218
  • plus $1K from 14 others

What the payments were for

  • Food & beverage$3,438100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,438 in reported general payments places this provider in the 85th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$162,740
Medicare patients
369
Services billed
1,471

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide49$87,130
EliquisApixaban39$42,776
MounjaroTirzepatide17$29,673
JardianceEmpagliflozin14$19,448
Spiriva RespimatTiotropium Bromide14$8,230
Atorvastatin Calcium337$3,571
SynthroidLevothyroxine Sodium40$3,360
Tamsulosin Hcl146$3,246
Lantus SolostarInsulin Glargine,hum.Rec.Anlog24$3,148
Levothyroxine Sodium226$3,117
Gabapentin92$2,485
Omeprazole147$2,334
Memantine Hcl ErMemantine Hcl11$2,109
Losartan Potassium230$2,084
Amlodipine Besylate194$1,408

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$817$87,13049 claims
PfizerEliquis$172$42,77639 claims
Lilly USA, LLCMounjaro$198$29,67317 claims
Boehringer IngelheimJardiance, Spiriva Respimat$28$27,67828 claims
AbbVieSynthroid$357$3,36040 claims
Teva Pharmaceuticals USA, Inc.Acyclovir$47$61113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 10,533 family medicine providers in California.

Other family medicine in San Diego

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →